chronic pulmonary hypertension epidemiology forecast

Key Highlights

• Chronic Pulmonary Hypertension prevalence is expected to rise, driven by aging populations, obesity trends, improved premature infant survival, environmental factors, genetic predisposition, enhanced diagnostics, and rising comorbidities.
• In 2023, the US accounted for the maximum diagnosed patient share of Chronic Pulmonary Hypertension in the 7MM, i.e., 42%, followed by Japan accounting for around 16% of the total 7MM cases. Among the European countries higher number of cases were in the UK accounting for about 11% of the total 7MM cases. 
• According to the analysis conducted by DelveInsight, Chronic Pulmonary Hypertension cases were in approximately 61% of females and 39% of males within EU4 and the UK in 2023. This analysis indicates a higher prevalence of Chronic Pulmonary Hypertension among females than males.
• The highest proportion of Chronic Pulmonary Hypertension cases was estimated in the 65 years and above age group in Japan, while age group of <45 years had least cases.

DelveInsight’s “Chronic Pulmonary Hypertension – Epidemiology – 2034” report delivers an in-depth understanding of the Chronic Pulmonary Hypertension, historical and forecasted epidemiology in the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan.

Geography Covered

• The United States
• EU4 (Germany, France, Italy, and Spain) and the United Kingdom
• Japan

Study Period: 2021-2034

Disease Understanding and Diagnostic Algorithm

Chronic Pulmonary Hypertension Overview

Chronic pulmonary hypertension is a condition marked by elevated blood pressure in the lungs, leading to strain on the heart and potentially life-threatening symptoms like shortness of breath and fatigue. The classification includes five groups: Group 1 comprises pulmonary arterial hypertension (PAH), Group 2 involves pulmonary hypertension due to left heart disease, Group 3 consists of pulmonary hypertension due to lung diseases and/or hypoxia, Group 4 entails chronic thromboembolic pulmonary hypertension (CTEPH), and Group 5 encompasses pulmonary hypertension with unclear multifactorial mechanisms. Early diagnosis is vital for improving outcomes and quality of life.

Chronic Pulmonary Hypertension Diagnosis

Diagnosing chronic pulmonary hypertension involves a combination of clinical evaluation, imaging studies, and specialized tests. Challenges may arise due to the nonspecific nature of symptoms and the need for distinguishing PH from other cardiovascular and respiratory conditions.

Diagnostic procedures include echocardiography to assess heart function and estimate pulmonary artery pressure, followed by confirmatory tests such as right heart catheterization, which directly measures pressures in the pulmonary arteries. Challenges may arise in interpreting results accurately, particularly in cases where other heart or lung conditions coexist, necessitating careful differential diagnosis.

Additionally, identifying the underlying cause of pulmonary hypertension is crucial for appropriate treatment. This may require further investigations such as ventilation-perfusion (V/Q) scans for suspected chronic thromboembolic pulmonary hypertension (CTEPH) or comprehensive assessment for associated conditions like connective tissue diseases. Collaboration among specialists, including cardiologists, pulmonologists, and radiologists, is essential for navigating these diagnostic challenges and ensuring timely and accurate management of chronic pulmonary hypertension.

Further details related to diagnosis are provided in the report…

Chronic Pulmonary Hypertension Epidemiology

For the purpose of designing the patient-based model for Chronic Pulmonary Hypertension the report provides historical as well as forecasted epidemiology segmented by Total Prevalent Cases of Chronic Pulmonary Hypertension, Group-specific Prevalent Cases of Chronic Pulmonary Hypertension, Group-specific Prevalent Cases of Chronic Pulmonary Hypertension , and Age-specific Prevalent Cases of Chronic Pulmonary Hypertension in the 7MM covering the United States, EU4 countries (Germany, France, Italy, and Spain) and the United Kingdom, and Japan, from 2021 to 2034. 

• The total prevalent cases of Chronic Pulmonary Hypertension in the US are expected to increase with a significant CAGR by 2034, from around 17,910 thousand cases in 2023 in the US.
• Among the European countries, Germany (26%) had the highest prevalent population of Chronic Pulmonary Hypertension, followed by the UK in 2023. On the other hand, Spain had the least diagnosed prevalent population around 15% of Chronic Pulmonary Hypertension in the same year.
• However, the prevalent cases of Chronic Pulmonary Hypertension are expected to decrease in Germany and Japan attributed to decrease in country population and other factors.
• In Japan, among prevalent cases of Chronic Pulmonary Hypertension, most cases were of Group II Chronic Pulmonary Hypertension (~5,724 thousand) in 2023. While least were in Group I Chronic Pulmonary Hypertension around 54 thousand in the same year.
• The Chronic Pulmonary Hypertension prevalent cases were segmented based on age in four age‐groups <45 years, 45-54 years, 55-64 years, 65 years and above. Our estimate suggests that in the US highest number of cases were in the age group 65 years and above (52%) and the least in <45 years (2%) in 2023.
• Assessments as per DelveInsight’s analysts show that the majority of cases of Chronic Pulmonary Hypertension are occupied by females in comparison to males. There were approximately ~6,806 thousand male and ~11,104 thousand female cases of Chronic Pulmonary Hypertension in 2023 in the US.

KOL Views

To gaze into the epidemiology insights of the real world, we take KOLs and SMEs’ opinions working in the domain through primary research to fill the data gaps and validate the secondary research. Industry Experts were contacted for insights on Chronic Pulmonary Hypertension evolving treatment landscape, patient reliance on conventional therapies, patient therapy switching acceptability, along with challenges related to accessibility, including KOL from Women’s Guild Lung Institute, the United States; Claude Bernard University, France; Graduate School of Medicine, Japan; Caro Research Institute, the United States, and others.

Delveinsight’s analysts connected with 50+ KOLs to gather insights; however, interviews were conducted with 15+ KOLs in the 7MM. Their opinion helps understand and validate current disease prevalence, gender involved with the disease, diagnosis rate, and diagnostic criteria.

Scope of the Report

• The report covers a segment of key events, an executive summary, descriptive overview of Chronic Pulmonary Hypertension, explaining its causes, signs and symptoms, and pathogenesis.
• Comprehensive insight has been provided into the epidemiology segments and forecasts, the future growth potential of diagnosis rate, disease progression, and treatment guidelines.
• The report provides an edge for understanding trends, expert insights/KOL views, and patient journeys in the 7MM.
• A detailed review of current challenges in establishing the diagnosis.

Chronic Pulmonary Hypertension Report Insights

• Patient Population
• Country-wise Epidemiology Distribution
• Prevalence of Chronic Pulmonary Hypertension
• Group-specific Prevalent Cases of Chronic Pulmonary Hypertension
• Gender-specific Diagnosed Prevalent Cases of Chronic Pulmonary Hypertension
• Age-specific Diagnosed Prevalent Cases of Chronic Pulmonary Hypertension 

Chronic Pulmonary Hypertension Report Key Strengths

• 11 years Forecast
• The 7MM Coverage 
• Chronic Pulmonary Hypertension Epidemiology Segmentation

Key Questions

Epidemiology Insights

• What are the disease risks, burdens, and unmet needs of Chronic Pulmonary Hypertension? What will be the growth opportunities across the 7MM concerning the patient population of Chronic Pulmonary Hypertension?
• What is the historical and forecasted Chronic Pulmonary Hypertension patient pool in the United States, EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan?
• Why do only limited patients appear for diagnosis? 
• Which country is more prevalent for Chronic Pulmonary Hypertension and why?
• What factors are affecting the diagnosis of the indication? 

Reasons to Buy

• Insights on patient burden/disease, evolution in diagnosis, and factors contributing to the change in the epidemiology of the disease during the forecast years.
• To understand the Chronic Pulmonary Hypertension prevalence cases in varying geographies over the coming years.
• A detailed overview of Group, Gender, and Age-specific diagnosed prevalence of Chronic Pulmonary Hypertension.
• To understand the perspective of key opinion leaders around the current challenges with establishing the diagnosis options.
• Detailed insights on various factors hampering disease diagnosis and other existing diagnostic challenges.